Introduction
Circulating angiotensin II (Ang II) plays an important role in the regulation of cardiovascular system and water-electrolyte balance, while the components of renin-angiotensin system are present in peripheral tissues such as vasculature, kidney, adrenal glands and hearts, acting as a local production system of Ang II. Ang II produced in the peripheral tissues binds to specific receptors through autocrine or paracrine system and exerts growth-promoting effects on tissue remodeling process [1] . Such cell proliferative action by Ang II is now highlighted and the inhibition of local Ang II production appears to become an important treatment for patients with renal [2] or cardiovascular diseases [3, 4] . Ang II exerts a multiple function through its specific receptor. By development of nonpeptide receptor antagonists and molecular cloning of Ang II receptors, Ang II receptors were primarily divided into type 1(AT1-R) and type 2 (AT2-R) subtypes [5, 6] . The knock-out mice for AT1-R [7, 8] and AT2-R [9, 10] cardiovascular disease in States and Europe. In this review, we will discuss the results of our current studies into the transcriptional control, cellular distribution and signal transduction mechanism of Ang II receptors using cell models and gene manipulated animals as well as potential issues on clinical application of AT1-R antagonists. A review of the early phase of the Ang II receptors has been published [5, 6, 11] .
Transcriptional Regulation of AT1-R Gene
The Ang II receptor isolated from adrenal [12] or vascular smooth muscle cells [13] by expression cloning strategy had a high affinity with AT1-R antagonist and termed as the AT1-R subtype. AT1-R has itself been shown to consist of subtypes, which are designated AT1a-R and AT1b-R [14] [15] [16] [17] . However, these AT1-R subtypes are limited to rodents (rat and mouse) and higher mammals exhibit only one type of AT1-R.
AT1-R has a structure of seven transmembrane spanning region coupled with G-protein and mainly present in vasculature, liver, kidney and adrenal gland (Table  1 ). In the brain or heart tissues the expression level of AT1-R is regulated in a cell-specific manner; AT1-R expression is very low in neurons or myocytes, whereas the glial cell or cardiac fibroblasts abundantly express AT1-R [18] . To define the cell-specific expression of AT1-R gene, we analyzed the promoter region of rat AT1-R gene using vascular smooth muscle cells (VSMC), glial cells and PC12 cells that can differentiate to the neurons in the presence of nerve growth factor. In 1 Kb of upstream region of AT1-R gene, there were three positively and one strong negatively regulatory regions (NRE) (Fig. 1 ) [18] . Nuclear protein that binds to the NRE was present only in PC12 cells but not in VSMC and glial cells, suggesting that the NRE plays a role in neuronspecific repression of AT1-R gene transcription. Further analyses using DNase foot printing revealed that the core element of the NRE is an AT-rich sequence (5'-TAATCTTTTATT TTA-3') located between -456 to -442 and 53 KDa of nuclear protein binds to this element, and that targeted deletion and mutation in this core sequence upregulated the promoter activity by about 3-fold [19] . Similar AT-rich sequence was reported to act as a silencer in other genes including human Ig heavy chain, human MHC class I, rat PRL and mouse Ig K. Given that the binding protein is detected only in the brain, but not in liver or kidney, this 53 KDa of nuclear protein may be a trans-acting factor to inhibit the AT1-R gene transcription in neurons.
Sites for the interaction with the RNA polymerase II transcriptional complex including TATA and GC boxes were found proximally upstream from the transcriptional start site of human and rat AT1a-R genes, and some important regulatory elements were also found in the 5'-flanking regions (Fig. 2 In vivo adrenal AT1a-R response to manipulations that are expected to change Ang II are interesting. Bilateral nephrectomy or infusion of captoril or losartan reduced adrenal AT1a-R as well as that in the brain stem without affecting AT1a-R in the kidney or aorta [28] . Another AT1a-R antatagonist TCV116 was found to down-regulate adrenal AT1b-R but not AT1a-R.
In the heart and aorta both AT1a-R and AT1b-R were down-regulated by TCV-116 [29] . Oral administration of ACE inhibitor and calcium channel blocker, which reduced systolic blood pressure, reduced adrenal AT1a-R mRNA levels, but increased it in the heart [30]. Thus, there appeared to be a differential regulation mechanism of AT1a-R between adrenal and other tissues. A: Cis-traps regulation of rat AT1-R gene promoter and core sequence of negatively regulatory element (NRE). P1, P2 and P3 indicate positively regulatory elements located at -560 to -489, -331 to -201 and -201 to -61. NRE is present between -489 and -331. B: NRE fragment of AT1a-R gene was cotransfected into vascular smooth muscle cells (A10), glial cells and PC12 cells with CAT expression vector containing -489 to +61 of AT1a-R gene. The CAT activity normalized with f3-Gal activity and protein content was expressed as a function of molar ratios of the elements over the test gene. C: DNA core sequence of NRE of the rat AT1-R gene promoter. Translational efficiency plays an important role in the protein expression. Currently, short open reading frame (sORF) was detected at upstream of the translational initiation site of f32 adrenergic receptor gene and shown to have an inhibitory effect on its translation [31] . This translational control by sORF is a rare mechanism and only 10% of vertebrate animal genes have the sORF. Interestingly, G-protein coupled receptors such as /31, a1, a2 adrenergic, muscarinic and substance P receptor genes contained the sORF. We also found one sORF in the 5' non-coding region of rat AT1-R gene (+21 to +57 relative to the cap site ) and examined the effect of this element in the translational regulation. The mutation in this sORF increased the protein expression level of AT1-R with no effect on AT1-R mRNA levels, indicating that the rat AT1-R protein expression is negatively regulated by the sORF on the translational level ( Fig. 3) [32]. Human AT1-R gene contained three sORF in the 5' non-coding region and the protein expression was regulated in a tissue-specific manner [33] . Thus, the presence of sORF may be an important role in a tissue-specific expression profile of AT1-R. Highly specific inhibitor of EGF-R (tyrophostin AG1478), but not that of PDGF-R (AG1495) greatly abolished Ang II-mediated ERK activation, during which EGF-R was phosphorylated and association of Shc to EGF-R was also observed. This transactivation was also confirmed in Ang II-induced DNA synthesis and c-fos expression. Thus, the mitogenic effect of Ang II that had been shown to be important cellular action turned out to be mainly due to transactivation mechanism of EGF-R (Fig. 4) . Very recently, the good review concerning tyrosine kinases activated by AT1-R was published [41, 42] .
AT1-R-

Transcriptional
Control of AT2-R
The second isoform of the Ang II receptor, AT2-R, has been defined as the receptor that binds to CGP42112 and a series of PD compounds [5, 6] . Its abundance in mesenchymal tissues of the developing fetus, the uterus, the adrenal medulla, pheochromocytoma and specific brain regions suggested new neuronal and developmental roles for AT2-R [5, 6, 43, 44] . This receptor had been thought to be different from a seven transmembrane receptor, since its ligand binding affinity was not reduced by stable GTP analogs and it did not show agonist-induced internalization.
The cDNA isolated from PC12 cells [45] or rat fetus [46] by expression cloning strategy encoded a protein with 363 amino acid residues, which corresponded to a theoretical molecular weight of 41,303 and showed seven transmembrane domain receptor, which included the highly conserved sequence Asp141-Arg142-Tyr143 in the N-terminal region of the second cytosolic loop. However, it shared only 32% amino acid sequence identity with AT1a-R.
In contrast with AT1-R, AT2-R expression was obviously influenced by multiple factors ( We isolated the gene containing the promoter region of rat AT2-R and analyzed the cis-traps interaction. This gene with a single transcription start site contained a TATA box and cAMP responsive element (CRE) was present in the promoter region [49] . Interestingly, cAMP analogues conferred the cAMP-mediated inhibition of the AT2-R gene transcription.
As almost genes containing a CRE motif were known to be upregulated by binding of ATF/CREB transcription factors to the CRE motif, this unique regulation by cAMP may suggest the presence of additional repressor factors that binds to CRE motif.
AT2-R-Mediated Signaling
In contrast with AT1-R, the AT2-R-mediating signaling appeared to be less established. Bottari , it was shown that AT2-R has an inhibitory effect on AT1-R-mediated proliferation action and in the latter experiment AT2-R decreased the AT1-R-mediated ERK activity. We also found using cardiac fibroblasts expressing both AT2-R and AT1-R that AT2-R stimulation inhibited AT1-R-mediated DNA synthesis and cell growth [57] . The mechanism of the action of AT2-R participating in this process seems to result from reduced ERK activity caused by the activation of ERK phosphatase 1, a protein tyrosine phosphatase that inactivates ERK by dephosphorylating the tyrosine phosphate group in ERK. The inactivation of ERK and accompanying increase in DNA fragmentation by Ang II in these AT2-R-bearing cells are reversed by pertussis toxin (PTX) and orthovanadate.
Yamada et al. [58] described that AT2-R signaling involves Gi or Go and activation of PTP.
Hayashida et al. [59] showed that a synthetic peptide containing a 22-residue sequence from the third cytosolic loop of rat AT2-R, when transferred into VSMC, suppresses the ERK activity and that this inhibition is reversed by PTX or orthovanadate.
These results suggest that third cytosolic loop plays a role in the activation of a Gimediated PTP that inhibits ERK.
In nuronal cultures isolated from neonatal rat hypothalamus or in non-differentiated NG108-15 cells (neuron like cell), activation of AT2-R was reported to elicit stimulation of outward K+ currents [60, 61] and to inhibit T-type Ca2+ current [62] . Inhibition of Ang II production by ACE inhibitors is now becoming a new major approach for treatment of hypertension, cardiovascular remodeling, heart failure and chronic renal diseases. We found that both AT1-R and AT2-R were present in cardiac myocytes isolated from neonatal rat hearts [64, 65] and their expression was increased in response to mechanical stretch-induced myocyte hypertrophy [65] . Cardiac fibroblasts express abundant amounts of only AT1-R (6-fold higher relative to that in myocyte) [64] , which did not respond to mechanical stretch [65] . Thus, it was considered that in normal hearts the main localization of AT1-R is fibroblast rather than myocytes and the major cell type expressing AT2-R in adult and neonatal hearts is myocytes. On the basis of these cellular distribution pattern, we examined the expression of AT1-R and AT2-R during cardiac remodeling due to cardiac hypertrophy [25], myocardial infarction [66] and cardiomyopathy [57] . In these pathological conditions, both AT1-R and AT2-R were upregulated and the increase of AT1-R was most remarkable in myocardial infarction. In cardiomyopathy using hereditary myopathic hamsters, AT1-R was increased in hypertrophic state but it was down-regulated in parallel with progression of heart failure, while the expression of AT2-R was increased in heart failure stage rather than in hypertrophic state [57] . Down-regulation of AT1-R in heart failure was also observed in human hearts (Ohkubo et al. unpublished data) . Interestingly, the increased expression of AT2-R in failing hearts was localized in regions with interstitial fibrosis and this was confirmed by both myopathic hamsters [57] and human hearts with dilated cardiomyopathy, suggesting a differential expression profile of AT1-R and AT2-R in failing hearts. Using cardiac fibroblasts isolated from failing myopathic hamster hearts, we examined the function of AT2-R. AT1-R-mediated increases in DNA synthesis and cell growth were significantly inhibited by AT2-R stimulation and also synthesis of extracellular matrix proteins such as fibronectin or collagen type 1 was suppressed by AT2-R [57] . Taken together, these findings demonstrate that AT2-R is re-expressed by cardiac fibroblasts present in fibrous regions in failing hearts and that the increased AT2-R exerts an anti-AT1-R action on the progression of interstitial fibrosis during cardiac remodeling by inhibiting both fibrillar collagen metabolism and growth of cardiac fibroblasts. Accumulated evidence suggested that the distribution ratio of AT2-R relative to AT1-R is higher in human hearts rather than in animal hearts [67, 68] . We also examined using ventricular samples obtained from autopsy or during operation and found that the distribution ratio of AT2-R relative to AT1-R is about 40% in non-failing hearts and the ratio is increased during heart failure state because of downregulation of AT1-R (Fig. 5 ) [69] . Ang II has multiple effects on renal function, including modulation of renal blood flow, glomerular filtration rate, tubular epithelial transport, renin release and cellular growth [70] . Autoradiography coupled with competitive binding studies has been used to characterize the distribution of Ang II receptor subtypes in the renal tissue. Using these techniques, the distribution of AT1-R and AT2-R subtypes within the kidney was shown to be species dependent.
For example, in the rat and rabbit kidneys Ang II receptors were essentially of the AT1-R [71] [72] [73] [74] [75] , while both AT1-R and AT2-R were present within the kidney of the opossum and of primates including humans [73] [74] [75] [76] [77] [78] . The distribution of renal Ang II receptors has been most extensively studied in the rat where the AT1-R binding sites are predominantly located in the glomeruli, the renal tubules and the renal vasculature [79, 80] . These observations in the rat kidney were further confirmed at mRNA levels using reverse transcriptase-polymerase chain reactions and in situ hybridization [81] [82] [83] ; large AT1-R mRNA signals were detected in the glomerulus, proximal tubules, cortical blood vessels and collecting ducts. Smaller AT1-R mRNA signals were present in medullary thick ascending limb and medullary collecting duct. Within the rat glomerulus, AT1-R mRNA was localized in mesangial areas, predominantly at the vascular pole and on the terminal portion of the afferent arteriole. In contrast, using mutant mice with a targeted replacement of the AT1-R loci by the lacZ, Sugaya et al. [7] found that the strong lacZ staining was detected in both afferent and efferent arterioles, which agreed with the observation using polyclonal antisera for the rat AT1-R [84] .
Analyses using Northern blot [85] or in situ hybridization [82] indicated that AT2-R mRNA was not detected in the rat or mouse kidneys. However, autoradiography revealed that in the rabbit the fibrous sheath around the kidney contained AT2-R binding sites [86] and in the rhesus monkey AT2-R binding sites were present on the juxtaglomerular apparatus and vasculature in the renal cortex [73] . With respect to localization of Ang II receptor subtypes in the human kidney, all studies were performed on the protein level by the while AT2-R is the major subtype in large cortical blood vessels. In contrast, Sechi et al. reported that AT1-R is present primarily in both glomeruli and cortical blood vessels and AT2-R protein is not expressed in the human kidney [75] . We also examined the cellular localization of AT1-R and AT2-R mRNAs in the human renal cortex using in situ hybridization [93] . Strong AT1-R mRNA signals were localized in interlobular arteries and tubulointerstitial fibrous regions and weaker signals were detected in glomeruli and proximal tubules.
AT2-R mRNA signals were highly localized in interlobular arteries (Fig. 6) , suggesting the positive role of AT2-R in renal blood flow [93] , which agrees with the diuretic effect by AT2-R antagonists [87] . Lo et al. isolated tubular function from hemodynamic action by maintaining a constant renal blood flow and found that AT2-R antagonist PD123319 markedly and rapidly increased diuresis and natriuresis from the rat kidney [88] . AT2-R agonist CGP42112A suppressed diuresis and natriuresis, indicating the role of AT2-R in sodium retention.
Inagami et al. also described that AT2-R knock-out mice did not show a diuretic response to PD123319 [42] .
Physiological
Function of AT2-R and AT1-R Identified by Gene Manipulated Animals
Ichiki et al. [9] and Hein et al. [10] eliminated the gene encoding AT2-R in mice by targeted deletion. Fig. 6 . Cellular localization of AT1-R and AT2-R mRNAs of the human kidney using in situ hybridization: Renal cortex samples were examined by in situ hybridization using specific antisense cRNA probes for AT1-R (panels A and D) and AT2-R (panels B and E) mRNAs and sense cRNA probes for AT2-R mRNA (panels C and F). Adjacent serial sections of panels A, B and C were from patient #1 and those of panels D, E and F were from patient #2. Strong signals for AT1-R mRNA (shown by red color) were localized in interlobular arteries and perivascular fibrous regions (indicated by yellow arrow) and tubulointerstitial regions surrounding the glomeruli (indicated by double arrows). Moderate densities of signals were observed in the glomeruli and weaker signals were present in proximal tubules. The AT2-R mRNA signal (shown by red color in panels B and E) was localized in interlobular arteries and there were no significant detectable signals in tubulointerstitial regions and proximal tubules. No AT2-R mRNA signals were observed when sense cRNA probes for AT2-R mRNA were used as a probe (panels C and F).
Resultant
AT2-R null mice exhibited elevated pressor sensitivity in response to intravenous infusion of Ang II and their basal blood pressures were increased (Table 1) . However, as AT2-R expression in adult cardiovascular system is very low, the underlying mechanism remains to be determined.
We generated cardiac targeted overexpression mice of AT2-R using amyosin heavy chain promoter [94] . This transgenic mice demonstrated no phenotypic changes and neonatal mortality in the transgenics did not differ from that in the nontransgenic animals, and there were no adult deaths.
No obvious morphological changes, such as myocyte necrosis or fibrosis, were observed in the atrial or ventricular myocardium, electro-cardiograms were normal and no arrhythmia or any conduction block was seen. Infusion of Ang II increased blood pressure and heart rate dose-dependently in wild-type mice, whereas in AT2-R transgenic mice these hemodynamic response was markedly inhibited (Fig.  7) . This AT2-R -mediated negative chronotropic effect was exerted by circulating Ang II in a physiological range that did not stimulate catecholamine release. Isolated hearts of AT2-R transgenic mice perfused using a Langendorff apparatus also showed decreased chronotropic responses to Ang II with no effects on left ventricular dp/dt max values. Although transient outward K+ currents and L-type Ca2+ current recorded from cardiomyocytes were not influenced by AT2 activation, this study indicated that overexpression of AT2 decreases the sensitivity of pacemaker cells to Ang II. Thus, these findings suggested that the increased sensitivity of AT2-R knock-out mice to pressor effect of Ang II was partly explained by the lack of AT2-R-mediated negative chronotropic action.
AT1-R knock-out mice demonstrated a decrease in blood pressure by 25 mmHg and hypertrophy of renin producing JG cell [7] . Although we examined the heart-to-body weight ratio of this mice, there was no significant difference from that in wild-type mice. In contrast, Hemn et al. produced cardiac-specific overexpression mice of AT1-R using a-myosin heavy chain promoter. The transgenic Changes in mean blood pressure and heart rate after Ang II infusion in anesthetized cardiac-specific AT2 transgenic (TG) mice : Mice (12-16 weeks, n=15 for wild and TG mice) were anesthetized with pentobarbital, and blood pressure and heart rate were directly measured with catheters placed in the carotid artery. Mice were then given a bolus administration of captoril (30 mg/kg body weight) followed by infusion of Ang II at similar doses used in the experiments in AT2 knock-out mice [24, 25] . After 10 min of captoril administration, Ang II diluted in saline was infused at different doses in a volume of 10 pl directly into the catheter. In the experiment to examine the effect of PD123319, PD123319 (10 mg per kg) was infused into mice (n=8) pretreated with captoril and after 20 min Ang II was infused. Changes (%) in blood pressure (B) and heart rate (D) are shown relative to the baseline levels after captoril treatment. The results are expressed as means ± SEM. *P<0.01, tP<0.05, vs. the levels in wild-type mice.
mice were dead during late fetal or neonatal stage mainly by arrhythmia and severe bradycardia and had huge size of atrial tissues, while the size of ventricle was similar to the wild-type 1901. Given that this promoter works in atrium during fetal period but not in ventricle, this finding indicated that AT1-R has a hyperplastic action and is involved in cardiac pacing mechanism. We also generated the same cardiac-specific transgenic mice of AT1-R and found that almost mice were dead in fetal or neonatal stage due to severe bradycardia, whereas the size of atrial tissues was not so large as that observed by Hemn et al. [90] . Although this appeared to result from the difference in the expression level of AT1-R in atrium, our mice confirmed AT1-Rmediated positive chronotropic effect. (Fig. 8 ) [91] . As mentioned above, AT2-R stimulation was shown to inhibit growth of cardiac fibroblast or production of extracellular matrix formation and to exert negative chronotropic effect, indicating that AT2-R stimulation has a novel cardioprotective effect. Moreover, it was shown that in human hearts the distribution ratio of AT2-R was high [65, 66] and the expression was further increased in heart failure state by down-regulation of AT1-R [92] . Very recently, the ELITE study to compare the effectiveness of AT1-R antagonist losartan and ACE inhibitor captopril was performed in elderly heart failure patients and the result showed that losartan had a better effect on the ratio of sudden death and hospitality [93] . These beneficial effects might be partly explained by the potential effect mediated by AT2-R. Important mega trials such as ELITE II (left ventricular volume as endpoint) and CARMEN (losartan vs. enalapril vs. carvedilol, mortality as endpoint) are now in progress in patients with heart failure.
Since blockade of the renin-angiotensin system is essential for the management for patients with heart failure [3, 4] and it is expected that AT1-R antagonists will be widely used for treatment of patients with cardiovascular diseases in the near future to a similar extent as ACE inhibitors, this novel cardioprotective effect of AT2 should be confirmed in clinical studies. 
